Organ on a Chip Market

Organ on a Chip Market: Focus on Products and Technologies - Distribution by Type of Product, Organ Type (Liver on a Chip, Heart on a Chip, Lung on a Chip and Other Organ on a Chip), Application Area, Purpose, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    172

  • Slides
    218

  • View Count
    10386

Organ On Chip Overview

The global organ-on-a-chip market is anticipated to grow at a compounded annual growth rate (CAGR) of 21% during the forecast period, mainly driven by the rise in research activity within the pharmaceutical industry. It is a well-known fact that almost 90% of the therapeutic interventions fail in clinical trials, resulting in significant economic losses to the pharmaceutical industry. The lack of effective preclinical prediction of drug responses in humans is one of the various reasons for drug’s failure to get approved. Animal testing for preclinical evaluation of drugs sometimes fails to identify toxicity signs caused by a drug in humans. Moreover, these clinical trials are quite expensive, time-consuming and are associated with several ethical concerns. In order to reform the drug approval process and use non-animal testing models for preclinical evaluations, the US democrats and republicans introduced the FDA Modernization Act in 2021. The U.S. Environmental Protection Agency (EPA) has also declared the termination of the funds granted for the studies on mammals by 2035. As a result, several pharmaceutical companies have opted to modernize their conventional testing methods in order to cope up with the increasing limitations associated with animal models. One such innovative technology, 'organ-on-chip’ has the potential to transform the drug discovery process by simulating the human physiological and functional environment on a microfluidic system. The use of such novel testing models in drug discovery and genotoxicity testing has been steadily increasing and the global organ-on-a-chip market is anticipated to witness significant market growth during the forecast period.

The image provides context on organ on a chip market. Owing to the various advantages over traditional animal-based testing models, organ-on-chip products and technologies are gradually becoming the preferred choice for research and development of new drug interventions This image provides a list of organ on chip products. Close to 40 players, worldwide, have taken initiatives to develop various organ-on chip products and technologies; the market is characterized by the presence of start-ups The infographic provides a detailed organ-on-a-chip market landscape. Around 80% of the organ-on-chip products are commercialized; of these, 40% products are used to mimic both organ and disease physiology by providing and maintaining cell-specific microenvironment in vitro

Key Market Insights

The Organ-on-a-Chip Market, 2022-2035: Focus on Products and Technologies - Distribution by Type of Product (Organ(s)-based Models and Disease(s)-based Models), Organ Type (Liver on a Chip, Heart on a Chip, Lung on a Chip and Other Organ on a Chip), Application Area (Cancer Research, Drug Discovery and Toxicity Testing, Stem Cell Research and Tissue Engineering and Regenerative Medicine), Purpose (Research and Therapy Development), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts market report features an extensive study of the current market landscape, market size and future potential of the organ-on-chip market based on an informed opinion on the likely adoption of products based on organ on chip technology, over the forecast period. The market report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this industry. Key takeaways of the organ-on-a-chip market are briefly discussed below.

Benefits of Organ-on-Chip Technology

The novel organ-on-chip models have various advantages over the traditional animal-based models, including fine control over microenvironment, lower cost, lesser time, easy to use and portable. Given the inherent benefits of organ-on-chip technology, a number of players have launched their proprietary products in order to expedite preclinical studies of novel drug interventions across a wide array of disease indications. 

Organ-on-Chip Market Landscape: Several Small Companies are Contributing to the Development of Organ on Chip Technology

We have identified more than 40 companies who are working to develop more than 140 products and technology platforms in the organ on chip market. The market is characterized by the presence of startups. There are several organ-on-chip models, including lung on a chip, liver on a chip, heart on a chip, brain on a chip and multiple organ models, which are being offered by various players. Apart from offering efficient user-friendly organ-on-chip models, some developers also offer customization of these models as per the client requests. It is worth mentioning that various developers have made significant efforts in developing organ-on-chip technologies, paving the way for new innovations, primarily integrating artificial intelligence driven technology for early detection of pharmaceuticals and toxicity risks, along with detection of unknown mutations.  

Organ-on-a-Chip Market Size: Driven by The Rising Demand for Drug Testing and Changing Regulatory Guidelines

Up till now, several pharmaceutical manufacturers and research institutions have embraced the use of these in vivo like in vitro models; however, a remarkable rise in the adoption rate of these models has been observed since the FDA changed its laws towards putting an end on the animal testing models. The rise in incidence of chronic diseases worldwide is driving the demand for novel treatment options, in turn leading to rise in the number of preclinical and clinical trials. Organ on a chip companies are launching new products to cater to the needs of the research community. Based on all these driving factors, the global market for organ-on-chip is anticipated to grow at a CAGR of 21% during the forecast period. 

Market Trends: Partnerships, Collaborations, Funding and More

As an increasing number of pharmaceutical companies are adopting the organ on chip technology within their drug development process, several partnerships have been established with organ on chip technology and device companies. In December 2022, Tessara Therapeutics entered in to collaboration with France based organ on chip company NETRI on development of next generation brain on a chip model for neurological disease research.

Owing to the presence of a number of startups, funding from investors plays a critical role in driving market growth. Over USD 680 million funding has been raised across more than 60 funding instances in a five-year period captured in the market report. More than 60% of the funding has been raised by organ on chip companies based in Europe. Netherlands based organ on a chip company Mimetas has raised the maximum funding during the period captured. Driven by promising benefits over animal testing, increasing R&D activity and financial support from investors, the organ-on-chip market size is anticipated to grow at a CAGR of 21% during the forecast period.

Technology Trends: Organ on Chip Companies Leading the Way Forward in to New Indications and Application in Industry Beyond Pharmaceutical

As with any other industry, the funds from private investors and grants are supporting the technological advancements in the organ-on-a-chip market. The chip developers are upgrading their products for use in new indications. Emulate, a US based organ-on-chip maker had launched an intestinal organ-on-a-chip in 2021 for research in the area of gastrointestinal diseases. In May 2022, they upgraded the organ chip to support drug development for inflammatory bowel disease indication. The company also launched Chip-A1 in June 2023, to serve the growing cancer research market. The Chip-A1 is also capable of serving the research needs of the cosmetics industry. Emulate Bio is a spin-out from Harvard University’s Wyss Institute and is leveraging the organ on a chip technology developed at the institute. Another US based company, Hesperos was spun out from the National Center for Advancing Translational Sciences (NCATS). It launched a human malaria-on-a-chip disease model in July 2023, working in collaboration with the Medicines for Malaria Venture (MMV). As the companies advance the development of organ on chip technology in new indications and new industries, the industry is bound to witness strong market growth during the forecast period.

Leading Organ on a Chip Companies 

Examples of key companies engaged in this industry (which have also been profiled in this report) include (in alphabetical order), BEOnchip, Dynamic42, Emulate, Mimetas, SynVivo, TissUse, and uFluidix. This organ-on-chip market report includes an easily searchable excel database of all the organ on chip companies worldwide.

The image provides a brand positioning matrix of organ-on-chip companies. Over time, stakeholders have established strong brand positions; in order to cater to increasing demand for organ-on-chips, a number of players have stepped up to introduce efficient, easy to use and advanced products This image highlights the level of innovation happening in the organ on a chip market. In order to protect the intellectual property generated within organ-on-chip field, both the industry and non-industry players have filed more than 420 patents in the past five years The infographic highlights the level of activity happening in organ on a chip market. With the growing interest in the field of organ-on-chips, several partnerships have been established between device / technology providers and other stakeholders

Recent Developments in Organ on a Chip Market

Several recent developments have taken place in the field of Organ on Chip. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In June 2023, MatTek Life Sciences announced a strategic partnership with AIM Biotech enabling the availability of AIM Biotech portfolio for sale through MatTek. 
  • In June 2023, Dynamic42 raised an undisclosed amount through a Series A funding round in order to expand internationally. 
  • In June 2023, Emulate launched Emulate Chip-A1™ to widen its applications in cancer and cosmetic markets. 

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in this industry, across different segments as defined in the table below:

Key Report Attributes Details

Base Year

2022

Forecast Period

2022 – 2035

CAGR 21%

Type of Product

Organ(s)-based Models, Disease(s)-based Models

Organ Type

  • Liver on a Chip
  • Heart on a Chip
  • Lung on a Chip
  • Other Organ on a Chip
Application Area
  • Cancer Research
  • Drug Discovery and Toxicity Testing,
  • Stem Cell Research
  • Tissue Engineering and Regenerative Medicine 
Purpose
  • Research
  • Therapy Development
Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
Key Companies Profiled
  • BEOnchip
  • Dynamic42
  • Emulate
  • Mimetas
  • SynVivo
  • TissUse
  • uFluidix
(Full list of more than 45 organ on chip companies captured in the market landscape analysis of the report)
Customization Scope 15% Free Customization Option
PowerPoint Presentation (Complimentary)

Available

Excel Data Packs (Complimentary)
  • Organ-on-Chip Products and Technology: Market Landscape
  • Organ on Chip Companies: Developer Landscape
  • Academic Grants Analysis
  • Partnerships and Collaborations
  • Funding and Investment Analysis 
  • Patent Analysis
  • Market Forecast and Opportunity Analysis

 

The image provides a view on interest from academia in organ on chip market. Close to 350 grants have been awarded for the ongoing R&D efforts for organ-on-chip products and technologies; National Center for Advancing Translational Sciences has awarded the maximum grant amount of USD 77 million Venture capitalists have also shown huge interest in organ on chip. The rising interest of investors within this upcoming segment is evident from the fact that over USD 680 million funding has been raised across more than 60 funding instances, over the last five years The image provides a detailed organ on a chip market forecast. The market is projected to grow at a CAGR of over 20%, till 2035; the forecasted opportunity is likely to be distributed across different application areas, type of product, purpose, and geographical regions

The research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in the organ-on-chip market, across different geographies. Amongst other elements, the report includes:

  • A general introduction of organ-on-chip, including history and development, classification, advantages and limitations and applications and future perspectives of organ-on-chip.
  • A detailed assessment of the current market landscape of organ-on-chips based on a number of relevant parameters, such as type of offering(s) (chip, plate / system, and technology), type of model(s) (organ(s)-based and disease(s)-based), organ type (liver on a chip, heart on a chip, lung on a chip and other organ on a chip), status of development (commercialized, developed, and under development), type of technology / platform, number of chips in a plate, material used for construction of chip / plate (polymer, glass and silicon), type of polymer (polydimethylsiloxane, cyclic olefin polymer, cyclic olefin copolymer, elastomer, polycarbonate, polypropylene, polystyrene, polyester, tygon, and styrene TEP), compatible tissue / organ, and application area (cancer research, drug discovery and toxicity testing, stem cell research, and tissue engineering and regenerative medicine). In addition, the chapter provides details on the organ on a chip companies engaged in the development of organ-on-chip products and technologies, along with information on their year of establishment, company size and location of headquarters.
  • Elaborate profiles of the key players developing organ-on-chips (which are presently commercialized), which are headquartered in North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, organ-on-chip product portfolio, recent developments, and an informed future outlook. 
  • An in-depth analysis of various patents that have been filed / granted for organ-on-chip, till 2022, based on various relevant parameters, such as type of patent, publication year, application year, issuing authorities involved, type of organizations, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed), patent characteristics and geography. It also includes an insightful patent valuation analysis.
  • A detailed brand positioning analysis of the key industry players, highlighting the current perceptions regarding their proprietary products by taking into consideration several relevant aspects, such as experience of the manufacturer, number of products and technologies offered, product diversity, and number of patents published.
  • A study of the various grants that have been awarded to research institutes engaged in projects related to organ-on-chip, between 2017 and 2022, based on parameters, such as year of award, support period, amount awarded, funding institute center, grant type, emerging focus area, type of recipient organization, key regions, and leading recipient organizations.
  • An analysis of the partnerships that have been established since 2017, covering various types of partnerships, such as research and development agreements, clinical trial agreements, product development and commercialization agreements, technology integration agreements, and product development and manufacturing agreements of the companies focused on developing organ-on-chip products and technologies.
  • An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in start-ups / small companies (with less than 50 employees) and mid-sized companies (with 51-200 employees) that are focused on developing organ-on-chip products and technologies.
  • A case study on scaffold-free 3D cell culture products, including hanging drop plate, 3D petri dish, and ultra-low attachment plate, featuring a list of more than 60 products that are being used for research and pharmaceutical testing, based on a number of relevant parameters, such as status of development (commercialized and developed, not commercialized), type of system (suspension system, attachment resistant and microfluidic system), type of product (ultra-low attachment plate, plate, hanging drop plate, chips and dish) and material used for fabrication (chemical / polymer based, human based and plant based).

One of the key objectives of the market report was to understand the primary growth drivers and estimate the future market size of organ-on-a-chip market. Based on multiple parameters, such as overall 3D cell culture market, and share of organ-on-chip, we have provided informed estimates of the evolution of the market for the forecast period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented on the basis of type of product (organ(s)-based models and disease(s)-based models), application area (cancer research, drug discovery and toxicity testing, stem cell research and tissue engineering and regenerative medicine), purpose (research and therapy development), key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were also influenced by discussions conducted with multiple stakeholders in this industry. The market report features detailed transcripts of discussions held with the following individuals (in alphabetical order of company / organization names): 

  • Pierre Gaudriault, (Chief Business Development Officer, Cherry Biotech)
  • Matt Dong-Heon Ha (Chief Executive Officer, EDmicBio)
  • Michael Shuler (President, Hesperos)
  • Jelena Vukasinovic (Chief Executive Officer, Lena Biosciences)
  • Maurizio Aiello (Chief Executive Officer, react4life)
  • Michele Zagnoni (Chief Executive Officer, ScreenIn3D)

Key Questions Answered

  • What is organ on a chip?
  • What is the value of organ-on-a-chip market?
  • Who are the key players engaged in the development of organ-on-chip products and      technologies?
  • What are the different application areas where organ-on-chip can be used?
  • Primarily in which geographical regions, are the organ-on-chip developers located?
  • How has the intellectual property landscape of organ-on-chip, evolved over the years?
  • Which partnership models are commonly adopted by stakeholders in the organ-on-chip domain?
  • What are the investment trends and who are the key investors actively engaged in the research and development of organ-on-chip systems?
  • How is the current and future opportunity likely to be distributed across key market segments?

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com